Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Pharmacotherapy. 2016 Jun 30;36(7):731–739. doi: 10.1002/phar.1771

Figure 1.

Figure 1

Study Flow.

1 Excluded due to concurrent therapy of linezolid and vancomycin and/or exposure to other anti-MRSA antibiotics during hospital admission

2Excluded due to mortality within 48 hours of linezolid initiation and/or received less than 2 consecutive days of therapy

3Excluded due to mortality within 48 hours of vancomycin initiation and/or received less than 2 consecutive days of therapy